TrialCurvePORTEC-3 (primary analysis): reconstructed Kaplan–Meier curves
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Oncol. 2018 Mar;19(3):295–309. doi: 10.1016/S1470-2045(18)30079-2 |
|---|---|
| DOI | 10.1016/S1470-2045(18)30079-2 |
| Registry | NCT00411138 |
| Phase | Phase 3 |
| Conditions | Endometrial Cancer |
| Interventions | Radiation Therapy, cisplatin, carboplatin, Paclitaxel |
| Sponsor | Leiden University |
| Enrolment | 670 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — All patients
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Chemoradiotherapy not reached; Radiotherapy not reached. Survival at 1 years: Chemoradiotherapy 94%; Radiotherapy 95%. Hazard ratio Chemoradiotherapy vs Radiotherapy 0.81 (95% CI 0.58–1.13).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Chemoradiotherapy | 330 | 62 | not reached |
| Radiotherapy | 330 | 77 | not reached |
- Chemoradiotherapy vs Radiotherapy: reconstructed HR 0.81 (95% CI 0.58–1.13)
Landmark survival (reconstructed)
| Time | Chemoradiotherapy | Radiotherapy |
|---|---|---|
| 1 yr | 94.2% | 95.5% |
| 2 yr | 88.2% | 89.1% |
| 3 yr | 83.2% | 82.6% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.76, reconstructed 0.809 pass
Failure-free survival — All patients
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Chemoradiotherapy not reached; Radiotherapy not reached. Survival at 1 years: Chemoradiotherapy 92%; Radiotherapy 87%. Hazard ratio Chemoradiotherapy vs Radiotherapy 0.73 (95% CI 0.54–0.98).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Chemoradiotherapy | 330 | 78 | not reached |
| Radiotherapy | 330 | 101 | not reached |
- Chemoradiotherapy vs Radiotherapy: reconstructed HR 0.73 (95% CI 0.54–0.98)
Landmark survival (reconstructed)
| Time | Chemoradiotherapy | Radiotherapy |
|---|---|---|
| 1 yr | 92.1% | 86.9% |
| 2 yr | 83.3% | 78.1% |
| 3 yr | 79.6% | 71.6% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.71, reconstructed 0.731 pass
Overall survival — Patients with stage III endometrial cancer
From figure panel C · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Chemoradiotherapy not reached; Radiotherapy not reached. Survival at 1 years: Chemoradiotherapy 93%; Radiotherapy 94%. Hazard ratio Chemoradiotherapy vs Radiotherapy 0.73 (95% CI 0.47–1.15).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Chemoradiotherapy | 152 | 34 | not reached |
| Radiotherapy | 143 | 43 | not reached |
- Chemoradiotherapy vs Radiotherapy: reconstructed HR 0.73 (95% CI 0.47–1.15)
Landmark survival (reconstructed)
| Time | Chemoradiotherapy | Radiotherapy |
|---|---|---|
| 1 yr | 93.4% | 94.4% |
| 2 yr | 86.2% | 85.3% |
| 3 yr | 79.5% | 75.4% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.71, reconstructed 0.73 pass
Failure-free survival — Patients with stage III endometrial cancer
From figure panel D · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Chemoradiotherapy not reached; Radiotherapy not reached. Survival at 2 years: Chemoradiotherapy 80%; Radiotherapy 67%. Hazard ratio Chemoradiotherapy vs Radiotherapy 0.63 (95% CI 0.43–0.93).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| Chemoradiotherapy | 152 | 45 | not reached |
| Radiotherapy | 143 | 59 | not reached |
- Chemoradiotherapy vs Radiotherapy: reconstructed HR 0.63 (95% CI 0.43–0.93)
Landmark survival (reconstructed)
| Time | Chemoradiotherapy | Radiotherapy |
|---|---|---|
| 1 yr | 91.4% | 81.7% |
| 2 yr | 80.2% | 66.9% |
| 3 yr | 74.8% | 60.5% |
| 5 yr | — | 57.7% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.66, reconstructed 0.633 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/portec-3-primary-analysis-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/portec-3-primary-analysis-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet Oncol. 2018 Mar;19(3):295–309. doi: 10.1016/S1470-2045(18)30079-2 doi:10.1016/S1470-2045(18)30079-2. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/portec-3-primary-analysis
Report a problem with these data
Related trials
- PORTEC-3: Overall survival; Recurrence-free survival
- COPELIA: Overall survival; Progression-free survival
- SCORES: Overall survival; Overall survival, final analysis
- Chemoradiotherapy ± simultaneous integrated boost in cervical cancer: Overall survival; Pelvic-specific PFS; Progression-free survival (PFS)
- NORA (final overall survival): Chemotherapy-free interval; Overall survival; Progression-free survival 2; Time to first s
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials